Keyphrases
A1 Receptor
17%
Abdominal Fat
13%
Active Commuting
37%
Active Leisure
15%
Bike
14%
Body Composition
19%
Cardiometabolic Health
25%
Cardiorespiratory Fitness
30%
Commute Time
27%
Dapagliflozin
29%
Exercise Affect
15%
Exercise Effect
24%
Exercise Group
26%
Exercise Intensity
13%
Exercise Intervention
14%
Exercise Training
23%
Gastric Emptying
14%
Glucagon-like
17%
Glucose-lowering Drugs
14%
Glycemic Variability
14%
Growth Differentiation factor-15 (GDF-15)
23%
Health Effects
17%
Healthy Weight
23%
Hemoglobin A1c (HbA1c)
34%
Insulin Sensitivity
28%
Leisure-time Exercise
41%
Liraglutide
32%
Metformin
42%
Metformin Treatment
13%
Moderate Intensity
20%
Obese Men
14%
Obesity
58%
Oral Glucose Tolerance Test
20%
Overweight or Obesity
63%
Per-protocol Analysis
16%
Physical Activity
26%
Physically Inactive
14%
Placebo
23%
Pre-diabetes (pre-DM)
79%
Randomized Controlled Trial
100%
Receptor Agonist
17%
Single Center
23%
Structured Exercise
23%
Time-restricted Feeding
25%
Type 2 Diabetes Mellitus (T2DM)
29%
Type 2 Diabetes Risk
37%
Vigorous Intensity
37%
VO2peak
23%
Weight Loss
15%
Weight Maintenance
23%
Medicine and Dentistry
Abdominal Obesity
11%
Adverse Event
9%
Antidiabetic Agent
13%
Arm
17%
Biological Marker
15%
Body Fat Percentage
7%
Body Mass Index
24%
Body Weight
28%
Carbohydrate Counting
11%
Cardiometabolic Risk
7%
Cardiovascular Disease
13%
Dapagliflozin
27%
Diabetes
15%
Diabetic Nephropathy
11%
Disease Exacerbation
6%
Drug Therapy
11%
Energy Balance
11%
Exercise
13%
Extracellular Matrix
11%
Glomerular Filtration Rate
5%
Glucagon
12%
Glucagon-Like Peptide-1 Agonist
23%
Glucose Intake
11%
Glucose Metabolism
6%
Glycated Hemoglobin
9%
Glycemic
19%
Glycemic Control
11%
Glycon
50%
Growth Differentiation Factor 15
11%
Hemoglobin A1c
35%
Hepcidin
11%
Impaired Glucose Tolerance
79%
Insulin Sensitivity
15%
Interstitial Fluid
11%
Liraglutide
31%
Low Calorie Diet
6%
Maturity Onset Diabetes of the Young
53%
Metabolic Syndrome
11%
Microalbuminuria
11%
Muscle Protein
11%
Obesity
39%
Open-Label Trial
6%
Oral Glucose Tolerance Test
18%
Physical Activity
17%
Placebo
27%
Post-Hoc Analysis
46%
Protein Expression
11%
Pyruvate Dehydrogenase
7%
Randomized Controlled Trial
63%
Skeletal Muscle
11%
